MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer

MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer

[...]the cell produces many mutated proteins that can be recognized as neo-epitopes by the immune system. [...]a relationship exists between the amount of somatic mutations and the clinical response to the treatment (10). [...]this trial has shown enthusiastic results that will permit more research...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunotherapy 2015-11, Vol.7 (11), p.1133-1134
Hauptverfasser: Aguiar, Pedro Nazareth, Tadokoro, Hakaru, Forones, Nora Manoukian, de Mello, Ramon Andrade
Format: Artikel
Sprache:eng
Schlagworte:
Animals
Antibodies, Monoclonal, Humanized - therapeutic use
Antigens, Neoplasm - genetics
Antigens, Neoplasm - metabolism
Antineoplastic Agents - therapeutic use
Brain Neoplasms - complications
Brain Neoplasms - immunology
Brain Neoplasms - therapy
Cancer therapies
Clinical Trials as Topic
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - complications
Colorectal Neoplasms - immunology
Colorectal Neoplasms - therapy
Epitopes
Gastric cancer
Humans
Hypotheses
Immune system
Immunogenicity
Immunotherapy
Lung cancer
Medical prognosis
Metastases
Metastasis
MMR
Monoclonal antibodies
Mutation
Mutation - genetics
Neoplasm Metastasis
Neoplastic Syndromes, Hereditary - complications
Neoplastic Syndromes, Hereditary - immunology
Neoplastic Syndromes, Hereditary - therapy
pembrolizumab
Programmed Cell Death 1 Receptor - immunology
Proteins
Response rates
Targeted cancer therapy
Tumor Escape - drug effects
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[...]the cell produces many mutated proteins that can be recognized as neo-epitopes by the immune system. [...]a relationship exists between the amount of somatic mutations and the clinical response to the treatment (10). [...]this trial has shown enthusiastic results that will permit more research in order to approve a new agent for metastatic colorectal cancer.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt.15.84